Trial Profile
Efficacy Evaluation of Metabolic, Anti-inflammatory, and Antioxidative Factors of Irbesartan/Atorvastatin Fixed-dose Combination in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension, With Adequately Controlled Blood Glucose Levels
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin/irbesartan (Primary) ; Atorvastatin; Irbesartan
- Indications Hyperlipidaemia; Hypertension
- Focus Therapeutic Use
- Sponsors Sanofi
- 18 May 2018 Status changed from recruiting to completed.
- 29 Mar 2018 Planned End Date changed from 1 May 2018 to 31 Jul 2019.
- 29 Mar 2018 Planned primary completion date changed from 1 May 2018 to 31 Jul 2019.